新型营养复方(BruMeChol™)对轻度高胆固醇血症受试者影响的随机双盲对照试验研究方案
该研究为随机、双盲、安慰剂对照、平行组临床试验方案,计划在意大利Ancona的IRCCS INRCA心脏病科开展12周,招募125名年龄≥40岁、总血清胆固醇≥200且≤250 mg/dl的轻度高胆固醇血症受试者。干预组每日两次、主餐前15分钟服用含植物甾醇、佛手柑果实黄酮提取物、橄榄果实黄酮提取物和维生素K2的胶囊,对照组服用安慰剂。主要终点为总胆固醇水平下降,次要终点为炎症生物标志物下降。
要点
- 每日两次主餐前15分钟服用含植物甾醇、佛手柑和橄榄黄酮提取物及维生素K2的胶囊。
- 受试者为年龄≥40岁、总血清胆固醇≥200且≤250 mg/dl的轻度高胆固醇血症患者。
- 主要终点为总胆固醇下降,次要终点包括IL-6、IL-32、IL-37、IL-38及inflamma-miRs等炎症标志物。
核心结论
- 该研究方案旨在评估BruMeChol™膳食补充剂对轻度高胆固醇血症受试者的降胆固醇和抗炎效果。
- 方案研究结果可能为后续大规模多中心临床试验的设计提供参考。
研究设计与样本
- 随机、双盲、安慰剂对照、平行组临床试验,为期12周,在意大利Ancona的IRCCS INRCA心脏病科开展。
- 计划招募125名年龄≥40岁、总血清胆固醇≥200且≤250 mg/dl的轻度高胆固醇血症受试者。
- 干预组每日两次、主餐前15分钟服用一粒含植物甾醇、佛手柑果实黄酮提取物、橄榄果实黄酮提取物和维生素K2的胶囊,对照组同法服用安慰剂。
- 在基线、治疗6周和12周时进行医学评估和临床化学检查,包括血脂谱、血糖、肾肝心/肌肉功能标志物、白细胞介素(IL-6、IL-32、IL-37、IL-38)及inflamma-miRs(miR-21和miR-146a)。
关键数值与推荐
- 主要终点为总胆固醇水平下降。
- 次要终点为炎症生物标志物下降。
- 纳入标准:年龄≥40岁,总血清胆固醇≥200且≤250 mg/dl。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated cholesterol levels and systemic inflammation are considered relevant risk factors for cardiovascular disease (CVD) development and progression. Increasing evidence suggests that cholesterol-lowering and inflammation-lowering nutraceuticals are useful in the management of moderate hypercholesterolemia. Here, we describe the study protocol of a clinical trial aimed to evaluate the cholesterol and inflammatory lowering effect of an innovative dietary supplement (BruMeChol™, Mivell S.r.l., Italy), composed of a mixture of extracts of bergamot and olive fruits in association with vitamin K2 in subjects with mild hypercholesterolemia. METHODS: The study was planned as a randomized, double-blind, placebo-controlled, parallel group clinical trial for 12 weeks at the Cardiology Unit of the IRCCS INRCA of Ancona, Italy. A total of 125 subjects (age ≥ 40 years) with mild hypercholesterolemia (total serum cholesterol levels ≥ 200 and ≤ 250 mg/dl) will be recruited. Intervention arm participants will take one capsule of dietary supplement two times a day, 15 min before the main meal. Control arm participants will receive one capsule of placebo in the same way. The dietary supplement capsule contains the following ingredients: phytosterols, flavonoid-rich extract of bergamot fruit (Citrus bergamia), flavonoid-rich extract of olive fruit (Olea europaea), and vitamin K2. Participants will undergo a medical evaluation and chemical-clinical examinations, which include lipid profile, glycemia, biomarkers of renal, liver and cardiac/muscular functions, interleukins (IL 6, IL-32, IL-37, and IL-38), and innovative mediators of inflammation such as inflamma-miRs (miR-21 and miR-146a), at baseline, and after 6 and 12 weeks of treatment. The decrease in total cholesterol levels and inflammatory biomarkers will be the primary and secondary endpoints of the study. DISCUSSION: This protocol study, planned to verify the effects of BruMeChol™ dietary supplementation in subjects with mild hypercholesterolemia, could also contribute to new study designs for next large-scale multicenter clinical trials. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry: ACTRN12619000170123 . Retrospectively registered on 5 February 2019.
引用
- Bonfigli AR, Protic O, Olivieri F, et al. Effects of a novel nutraceutical combination (BruMeChol™) in subjects with mild hypercholesterolemia: study protocol of a randomized, double-blind, controlled trial. Trials. 2020. PMID: 32631422. doi:10.1186/s13063-020-04551-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。